Emmaus Life Sciences, Inc.
EMMA
$0.0115
-$0.0024-17.27%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -47.61% | -3.99% | -53.42% | 9.17% | -50.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.61% | -3.99% | -53.42% | 9.17% | -50.02% |
| Cost of Revenue | -37.76% | -12.45% | 61.78% | 84.11% | -52.56% |
| Gross Profit | -48.07% | -3.02% | -56.62% | 5.83% | -49.90% |
| SG&A Expenses | -31.68% | -37.89% | -36.45% | -5.70% | -33.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.53% | -35.46% | -32.62% | -6.75% | -35.49% |
| Operating Income | -163.57% | 64.23% | -141.11% | 3,320.83% | -82.50% |
| Income Before Tax | 19.88% | 46.59% | -258.80% | 1,639.05% | -35.24% |
| Income Tax Expenses | -2,003.23% | 157.14% | 105.36% | -102.63% | 191.18% |
| Earnings from Continuing Operations | 48.03% | 46.41% | -244.58% | 2,626.87% | -40.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.03% | 46.41% | -244.58% | 2,626.87% | -40.18% |
| EBIT | -163.57% | 64.23% | -141.11% | 3,320.83% | -82.50% |
| EBITDA | -162.24% | 64.34% | -140.56% | 2,481.25% | -82.37% |
| EPS Basic | 48.41% | 48.08% | -225.11% | 2,283.33% | -16.95% |
| Normalized Basic EPS | -13.21% | 61.03% | -218.06% | 103.41% | -3.92% |
| EPS Diluted | 48.41% | 48.08% | -279.78% | 2,140.00% | -16.95% |
| Normalized Diluted EPS | -13.21% | 61.03% | -218.06% | 105.88% | -3.92% |
| Average Basic Shares Outstanding | 0.81% | 3.27% | 15.74% | 19.07% | 19.84% |
| Average Diluted Shares Outstanding | 0.81% | 3.27% | 15.74% | 17.60% | 19.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |